Cormedix Stock News

CorMedix Inc (NASDAQ: CRMD ) has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the FDA. In parallel, the Company''s third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter issued by the FDA concurrently with the CRL. In March last … Full story available on Benzinga.com

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD ), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) a year ago. In parallel, the Company''s third-party manufacturer submitted responses to the deficiencies identified at the manufacturing facility in the Post-Application Action Letter ("PAAL") issued by the FDA concurrently with the CRL. DefenCath is being developed as a catheter lock solution with an initial indication of use for the reduction of catheter-related bloodstream infections (CRBSIs) in patients with renal failure who are receiving chronic hemodialysis via a central venous catheter. The FDA has 30 days to review the submission for completeness to accept for filing and provide guidance on the review timeline.

Spire Wealth Management increased its holdings in shares of CorMedix Inc. (NYSEAMERICAN:CRMD) by 166.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,200 shares of the biotechnology companys stock after buying an additional 7,000 shares during the period. Spire Wealth []

State Street Corp cut its stake in CorMedix Inc. (NYSEAMERICAN:CRMD) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 630,654 shares of the biotechnology companys stock after selling 35,957 shares during the period. State Street Corps holdings in []

CorMedix Inc. (NYSEAMERICAN:CRMD) Director Myron Kaplan purchased 10,000 shares of the stock in a transaction that occurred on Tuesday, November 16th. The stock was bought at an average price of $5.14 per share, with a total value of $51,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available []

Zacks Investment Research downgraded shares of CorMedix (NYSEAMERICAN:CRMD) from a hold rating to a sell rating in a research report report published on Friday morning, Zacks.com reports. According to Zacks, CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company []

CorMedix Inc. (NYSEAMERICAN:CRMD) Equities research analysts at Truist Securiti decreased their FY2021 earnings estimates for CorMedix in a research report issued on Tuesday, November 9th. Truist Securiti analyst J. Lee now anticipates that the biotechnology company will post earnings of ($0.76) per share for the year, down from their prior forecast of ($0.69). Truist []

CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. (CRMD) CEO Matt David on Q3 2021 Earnings Call Transcript

BERKELEY HEIGHTS, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an

BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an

BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an

New York, New York--(Newsfile Corp. - September 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CorMedix Inc. (NASDAQ: CRMD) between July 8,

NEW YORK, NY / ACCESSWIRE / September 19, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to par